{"date":"2025-04-06","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6589-2025-04-06-1152-3h3poe","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-04-06","time":"11:52:01","subject":"本公司向墨西哥聯邦衛生風險保護委員會遞交研發中產品EG1206A(pertuzumab生物相似藥)第三期臨床試驗計畫書","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-04-06 11:52，「本公司向墨西哥聯邦衛生風險保護委員會遞交研發中產品EG1206A(pertuzumab生物相似藥)第三期臨床試驗計畫書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}